Fig. 3

Differential pathway enrichment and prognostic implications of SLC25A13 expression in gliomas. Statistical significance is denoted as follows: ns (not significant, p > 0.05), *(p < 0.05), **(p < 0.01), ***(p < 0.001), and **** (p < 0.0001). A Hallmark gene set enrichment analysis for high and low SLC25A13 expression groups in glioblastoma multiforme (GBM). B Spearman correlation of SLC25A13 expression with quantification of functional proteins in TCPA-RPPA database at the pathway level. C Spearman correlation of SLC25A13 with GSVA scores for 14 functional states in gliomas. D Meta-analysis using inverse variance method for SLC25A13-related overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in TCGA LGG cohort. E Association of SLC25A13 expression with different clinicopathologic features in TCGA pan-glioma cohort. Differences between the two groups were assessed using the Wilcoxon rank-sum test. F Correlation between SLC25A13 expression quartiles and immune response scores in gliomas